MarginsXMarginsX
Home › Markets › Health Care › CORT

Corcept Therapeutics Incorporated (CORT)

CORT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$69.22
-5.10% on the day
Market cap
$7.6B
Mid cap
Revenue · 2025
$761.4M
+12.8% on 2024
Net income · 2025
$99.7M
13.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1088856/000162828026011091/0001628280-26-011091-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCORT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2004
SEC CIK0001088856
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$761.4M
Net income$99.7M
Operating income$44.8M
Net margin13.1%
Operating margin5.9%
Revenue growth+12.8%
Cash$120.5M
Total assets$836.7M
P/E (computed)76.0×
P/S (computed)9.9×

Warning signs

Cash runway
Cash-flow positive
$98.7M cash at September 30, 2026
Share count, 1 year
+4.0%
2025-10-23 to 2026-10-22 · +6.2% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$99.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$98.7M cash; operating cash flow $49.5M a quarter.Report 2026-09-30
Shares outstanding109,443,109 (2026-10-22); 105,188,217 a year earlier; 103,081,357 three years earlier.Cover page 2026-10-22
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $3.3M, sold $102.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$340.5M$126.8M$142.9M$98.7MNo debt tags$963.6M10-Q 2026-11-03
Q2 2026
2026-06-30
$256.1M$43.0M$33.5M$111.0MNo debt tags$830.8M10-Q 2026-07-29
Q1 2026
2026-03-31
$164.9M-$31.8M-$16.8M$108.7MNo debt tags$769.1M10-Q 2026-04-30
Q4 2025
2025-12-31
$202.1M$24.3M$38.4M$120.5MNo debt tags$761.4M10-K 2026-02-24
Q3 2025
2025-09-30
$207.6M$19.7M$54.5M$125.1MNo debt tags$741.2M10-Q 2026-11-03
Q2 2025
2025-06-30
$194.4M$35.1M$44.3M$102.7MNo debt tags$716.1M10-Q 2026-07-29
Q1 2025
2025-03-31
$157.2M$20.5M$4.8M$89.8MNo debt tags$685.4M10-Q 2026-04-30
Q4 2024
2024-12-31
$181.9M$30.7M$60.1M$127.7MNo debt tags$675.0M10-K 2026-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32017-03-13
Latest annual report10-K2026-02-24
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-03
Latest proxyDEF 14A2026-04-17

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.2%
1 month-38.1%
3 months-34.0%
Year to date+109.6%
1 year-3.7%
From 52-week high-41.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RYTMRhythm Pharmaceuticals Inc.$107.48-6.56%$7.5B
CYTKCytokinetics Incorporated$53.17-5.27%$7.4B
KNSAKiniksa Pharmaceuticals International plc$94.23-2.18%$7.4B
AMRXAmneal Pharmaceuticals Inc.$21.23-0.70%$7.4B
ALKSAlkermes plc$46.53-1.06%$7.8B
ABVXAbivax SA$83.61-4.53%$7.3B
AXSMAxsome Therapeutics Inc.$137.01-3.30%$7.2B
PTGXProtagonist Therapeutics Inc.$124.83-4.67%$8.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier